Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2021.563 | A Phase 2 Study of Magrolimab Combination Therapy in Patients With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer |
Prof. YEO Winnie 楊明明教授 |
| 2018.179 | A Phase 2 Study of Oraxol in Subjects with Cutaneous Angiosarcoma |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2018.271 | A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects with IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy including Dense Deposit Disease |
Prof. SZETO Cheuk Chun 司徒卓俊 |
| 2021.297 | A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Conatining VIR-2218, VIR-3434, and/or PEG-IFNa in Subjects with Chronic Hepatitis B Virus Infection |
Prof. WONG Grace Lai Hung 黃麗虹 |
| 2021.316 | A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects with Chronic Hepatitis B Virus Infection | Dr. YIP Wai Man |
| 2021.556 | A phase 2 trial of TAS 102 in recurrent/metastatic nasopharyngeal carcinoma |
Prof. MA Brigette Buig Yue 馬碧如 |
| 2006.317 | A Phase 2, 12-Week, Double-Blind, Dose-Finding, Placebo-Controlled Study to Assess the Efficacy and Safety of A Range of SCH 420814 Doses (1mg BID, 2mg BID, 5mg BID, and Possibly 10mg BID) in Subjects with Moderate to Severe Parkinson | Dr. Mok C.T. Vincent |
| 2007.420 | A Phase 2, 36-Week, Open-Label, Uncontrolled Safety Follow-up Study Assessing SCH 420814 5 mg BID | Prof. Mok C.T. Vincent |
| 2003.180 | A Phase 2, Double-Bind, Dose-Finding, Placebo-Controlled Study to Assess the Efficacy and Safety of SCH 420814 as Monotherapy in Subjects with Early Parkinson's Disease | Prof. Wong Ka Sing Lawrence |
| 2010.336 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of FG-3019 in Subjects with Liver Fibrosis due to Chronic Hepatitis B Infection | Prof. CHAN Henry Lik Yuen |
| 2010.530 | A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of FG-3019 in Subjects with Liver Fibrosis due to Chronic Hepatitis B Infection | Dr. HUI Aric Josun |
| 2024.625 | A Phase 2, Double-Masked, Randomised, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Orally Administered VX-01 in Diabetic Retinopathy of Non-Proliferative Type (NPDR) | Dr. BRELEN Marten |
| 2014.482 | A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy | Prof. SZETO Cheuk Chun |
| 2007.230 | A Phase 2, Multicenter, Open Label, Randomized Trial of AMG 706 or Bevacizumab in Combination with Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer | Prof. Mok S.K. Tony |
| 2009.594 | A Phase 2, Multicenter, Randomized Study of Two Different Dose Regimens of Eribulin Mesylate in Combination with Intermittent Erlotinib in Patients with Previously Treated, Advanced Non-Small Cell Lung Cancer | Prof. MOK Tony Shu Kam |
| 2008.399 | A Phase 2, Open Label, Trial of PF-00299804 in Selected Patients with Untreated Advanced Adenocarcinoma of the Lung | PROF. MOK TONY S.K. |
| 2024.441 | A Phase 2, Open-label Study Evaluating STRO-002, an Anti-folate Receptor Alpha (FOLR1) Antibody-Drug Conjugate, in Subjects with Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Expressing FOLR1 | Dr. LOONG Herbert Ho Fung |
| 2022.070 | A Phase 2, Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2017.530 | A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) from Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV) in Virologically Suppressed Chronic Hepatitis B Subjects with Renal and/or Hepatic Impairment |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2017.531 | A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) from Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV) in Virologically Suppressed Chronic Hepatitis B Subjects with Renal and/or Hepatic Impairment |
Dr. HUI Aric Josun 許祖紳醫生 |
| 2016.190 | A Phase 2, Open-Label, Randomized Two-part, Multiple Dose Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected with Chronic Hepatitis B Virus |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2024.456 | A Phase 2, Open-Label, Single-Arm Study of Amivantamab and Lazertinib Combination Therapy as First-Line Treatment in Patients with EGFR-Mutated Recurrent Non-Small Cell Lung Cancer after Previous Treatment with Adjuvant Osimertinib in Early-Stage Disease | Dr. LI Molly Siu Ching |
| 2012.200 | A Phase 2, Randomized Study to Evaluate the Efficacy and Safety of MEDI-546 in Subjects with Systemic Lupus Erythematosus | Prof. TAM Lai Shan |
| 2008.198 | A Phase 2, Randomized Trial of Chemoradiation with or without Panitumumab in Subjects with Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck | Prof. CHAN Anthony T.C. |
| 2020.303 | A Phase 2, Randomized, Double-blind, Double-dummy, Placebo-controlled, Dose-ranging, Dose-finding, Parallel Group Study to Assess Efficacy and Safety of PF 06865571 (DGAT2i) Alone and When Coadministered with PF-05221304 (ACCi) in Adult Participants with Biopsy-confirmed Nonalcoholic Steatohepatitis and Fibrosis Stage 2 or 3 |
Prof. WONG Vincent Wai Sun 黃煒燊 |
| 2020.309 | A Phase 2, Randomized, Double-blind, Double-dummy, Placebo-controlled, Dose-ranging, Dose-finding, Parallel Group Study to Assess Efficacy and Safety of PF 06865571 (DGAT2i) Alone and When Coadministered with PF-05221304 (ACCi) in Adult Participants with Biopsy-confirmed Nonalcoholic Steatohepatitis and Fibrosis Stage 2 or 3 | Dr. YIP Wai Man |
| 2009.223 | A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal Carcinoma | Professor Ma Brigette |
| 2018.151 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects with Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH) |
Prof. WONG Vincent Wai Sun 黃煒燊 |
| 2016.606 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Nonalcoholic Steatohepatitis (NASH) |
Prof. WONG Vincent Wai Sun 黃煒燊 |
| 2015.459 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects with Advanced Hepatocellular Carcinoma |
Prof. CHAN Lam 陳林 |
| 2015.535 | A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adolescent, Adult, and Elderly Hospitalized Patients With Influenza A Infection |
Prof. LEUNG Ting Fan 梁廷勳 |
| 2024.240 | A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma | Prof. HUI David Shu Cheong |
| 2015.703 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 in combination with Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects with Chronic Hepatitis B and who are currently not on Treatment |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2013.531 | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ADMINISTRATION OF A CHEMOKINE CCR2/5 RECEPTOR ANTAGONIST (PF-04634817) IN ADULTS WITH TYPE 2 DIABETES AND OVERT NEPHROPATHY | Dr Ozaki Risa |
| 2012.134 | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE-DAILY ADMINISTRATION OF A PHOSPHODIESTERASE 5 INHIBITOR (PF-00489791) IN ADULTS WITH TYPE 2 DIABETES AND OVERT NEPHROPATHY | Dr Ozaki Risa |
| 2009.163 | A Phase 2, Randomized, Double-Masked, Placebo-Controlled Study of the Safety, Pharmacokinetics and Biological Effects of Intravenous Fosbretabulin in Asian Subjects with Polypoidal Choroidal Vasculopathy (PCV) | Dr Lai Timothy Yuk Yau |
| 2018.472 | A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined with Intravesical BCG in Participants with BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer (CheckMate 9UT: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9UT) |
Dr. POON Darren Ming Chun 潘明駿 |
| 2021.154 | A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073) |
Dr. CHAN Stephen Lam 陳林 |
| 2025.096 | A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in combination with chemoradiation followed by durvalumab in locally advanced and unresectable Stage III non-small cell lung cancer | Dr. LOONG Herbert Ho Fung |
| 2018.297 | A Phase 2, Randomized, Open-Label, Active-Controlled Study to Evaluate the Safety and Antiviral Activity of GS-9992 Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Chronic Hepatitis B (CHB) Subjects |
Prof. WONG Grace Lai Hung 陳力元教授 |
| 2018.344 | A Phase 2, Randomized, Open-Label, Active-Controlled Study to Evaluate the Safety and Antiviral Activity of GS-9992 Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Chronic Hepatitis B (CHB) Subjects |
Dr. AU Kenneth Hon Da 許祖紳醫生 |
| 2007.307 | A Phase 2, Randomized, Parallel Group, Multi-Center, Multi-National Study for the Evaluation of Safety and Efficacy of Two Fixed Dosages of DU-176b in Subjects with Non-Valvular Atrial Fibrillation | Prof. Yu Cheuk Man |
| 2021.147 | A Phase 2, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients with Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT) |
Prof. POON Wai Sang 潘偉生 |
| 2020.258 | A Phase 2, Single Arm, Multi-center, Open-Label Trial to Evaluate the Safety and Efficacy of Treatment with Tumor Treating Fields (TTFields) and Chemotherapy as First-Line Treatment for Subjects with Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Gastric (GC) Adenocarcinoma. |
Prof. YEO Winnie 楊明明 |
| 2015.579 | A Phase 2, Uncontrolled, Three-Stage, Dose-Escalation Cohort Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Clinical Activity of OMS721 in Adults with Thrombotic Microangiopathies |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2022.448 | A Phase 2/3 Double-Masked, Randomized, 2-stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema |
Prof. CHEN Guy Lijia 陳理佳 |
| 2002.231 | A Phase 2/3 Open Label Multicenter Study of Doxorubicin Hydrochloride Adsorbed to Magnetic Targeted Carriers Administered by Intrahepatic Delivery Versus Intravenous Doxorubicin for Treatment of Patients with Unresectable Hepatocellular Carcinoma( Revised : CRE-2002.150-T) | Prof. Mok Tony |
| 2021.641 | A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT-232 in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) who are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2013.296 | A Phase 2/3, Multi-Center, Open Label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (BAX855) Administered for Prophylaxis and Treatment of Bleeding in Previously Treated Patients with Severe Hemophilia A | Dr. Wong Siu Ming Raymond |
| 2003.088 | A Phase 2/3, Multicenter, Randomized, Controlled, Open-Label Study of Intravenous T138067-Sodium versus Intravenous Doxorubicin in Subjects with Chemotherapy-Na_ve, Unresectable Hepatocellular Carcinoma | Prof. Mok SK Tony |
Page 17 of 262.